Inhibition of poly(ADP‐ribose) polymerase prevents irinotecan‐induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma-Reference-Cited by-同舟云学术

Inhibition of poly(ADP‐ribose) polymerase prevents irinotecan‐induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma

Published:2006-06-29 Issue:10 Volume:20 Page:1709-1711
ISSN:0892-6638
Container-title:The FASEB Journal
language:en
Short-container-title:FASEB j.

Author:

Tentori Lucio¹,Leonetti Carlo²,Scarsella Marco²,Muzi Alessia¹,Mazzon Emanuela³,Vergati Matteo¹,Forini Olindo¹,Lapidus Rena⁴,Xu Weizheng⁴,Dorio Annalisa Susanna¹,Zhang Jie⁴,Cuzzocrea Salvatore³,Graziani Grazia¹,Tentori Lucio¹,Leonetti Carlo²,Scarsella Marco²,Muzi Alessia¹,Mazzon Emanuela³,Vergati Matteo¹,Forini Olindo¹,Lapidus Rena⁴,Xu Weizheng⁴,Dorio Annalisa Susanna¹,Zhang Jie⁴,Cuzzocrea Salvatore³,Grazia Grazia¹

Affiliation:

1. Department of NeuroscienceUniversity of Rome “Tor Vergata,”RomeItaly

2. Experimental Clinical LaboratoryInstitute for Cancer Research “Regina Elena,”RomeItaly

3. Department of Clinical and Experimental Medicine and PharmacologyUniversity of Messina“Centro Neurolesi Bonino-Pulejo” (IRCCS)MessinaItaly

4. MGI PharmaBaltimoreMarylandUSA

Publisher

Wiley

Subject

Genetics,Molecular Biology,Biochemistry,Biotechnology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1096/fj.06-5916fje

Reference48 articles.

1. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

2. Mechanisms of resistance to topoisomerase I-targeting drugs

3. Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models;Houghton P. J.;Clin. Cancer Res.,2000

4. Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft;Patel V. J.;Clin. Cancer Res.,2000

5. Trial of irinotecan and temozolomide in patients with solid tumors;Jones S. F.;Oncology,2003

Cited by 94 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2;JCO Precision Oncology;2024-06

2. A carrier-free supramolecular nano-twin-drug for overcoming irinotecan-resistance and enhancing efficacy against colorectal cancer;Journal of Nanobiotechnology;2023-10-28

3. DNA repair biomarkers to guide usage of combined PARP inhibitors and chemotherapy: A meta-analysis and systematic review;Pharmacological Research;2023-10

4. A Carrier-Free Supramolecular Nano-Twin-Drug for Overcoming Irinotecan- Resistance and Enhancing Efficacy against Colorectal Cancer;2023-08-17

5. NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors;Cancer Research Communications;2023-06-26